非酒精性脂肪肝
医学
脂肪变性
胰岛素抵抗
脂肪肝
减肥
内科学
肥胖
慢性肝病
胃肠病学
利拉鲁肽
糖尿病
2型糖尿病
内分泌学
疾病
肝硬化
出处
期刊:PubMed
日期:2018-10-30
卷期号:40 (5): 597-602
标识
DOI:10.3881/j.issn.1000-503x.10524
摘要
Nonalcoholic fatty liver disease(NAFLD)refers to hepatic steatosis without other known causes such as alcohol abuse or hepatic virus infection. NAFLD has become a chronic disease worldwide,and its prevalence is constantly growing. Hepatic insulin resistance caused by obesity results in the deposition of triglycerides in the liver,promoting the occurrence and development of NAFLD. Weight loss is the only safe and effective method for NAFLD. Lifestyle intervention plays a cornerstone role in treating NAFLD;however,most patients can not achieve and maintain the ideal body weight by lifestyle intervention alone. Glucagon-like peptide-1 receptor agonist and metabolic surgery are promising treatments for NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI